{"analyses":[{"ciLowerLimit":".449","ciPctValue":"95","ciUpperLimit":".922","groupDescription":"Estimate of the proportion of negative minimal residual disease.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Binomial proportion","paramValue":".733","statisticalMethod":"Binomial proportion","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"To estimate the proportion of minimal residual disease (MRD)+ patients who become MRD- after one course of gemtuzumab ozogamicin (GO)","groups":[{"description":"Post-GO Treatment MRD","id":"OG000","title":"Overall"}],"paramType":"NUMBER","populationDescription":"Sixteen patients received GO treatment during consolidation I. One patient with negative MRD received GO treatment, which was not consistent with the protocol definition. 15 patients were analyzed. Out of the 15 patients, 7 patients were treated on HDAC arm and 8 patients were treated on LDAC arm.","reportingStatus":"POSTED","timeFrame":"Consolidation I","title":"Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)","type":"SECONDARY","unitOfMeasure":"Participants"}